Updates are available Correction dated 2023-12-09
Click to view Correction: https://doi.org/10.1007/s10157-023-02436-9
-
Authors
Yanagita, Motoko
Muto, Satoru
Nishiyama, Hiroyuki
Ando, Yuichi
Hirata, Sumio
Doi, Kent
Fujiwara, Yutaka
Hanafusa, Norio
Hatta, Takahiro
Hoshino, Junichi
Ichioka, Satoko
Inoue, Takamitsu
Ishikura, Kenji
Kato, Taigo
Kitamura, Hiroshi
Kobayashi, Yusuke
Koizumi, Yuichi
Kondoh, Chihiro
Matsubara, Takeshi
Matsubara, Kazuo
Matsumoto, Koji
Okuda, Yusuke
Okumura, Yuta
Sakaida, Emiko
Shibagaki, Yugo
Shimodaira, Hideki
Takano, Nao
Uchida, Akiko
Yakushijin, Kimikazu
Yamamoto, Takehito
Yamamoto, Kazuhiro
Yasuda, Yoshinari
Oya, Mototsugu
Okada, Hirokazu
Nangaku, Masaomi
Kashihara, Naoki
- License Information
-
More Information
Article History
Accepted: 21 September 2023
First Online: 25 October 2023
Change Date: 9 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10157-023-02436-9
Declarations
:
: M. Yanagita has received honoraria from Astellas Pharma Inc, AstraZeneca, Kyowa Kirin Co., Ltd., Chugai-Pharmaceutical Co., Ltd., Bayer AG, and Mitsubishi Tanabe Pharma, and research grants from Mitsubishi Tanabe Pharma, Boehringer Ingelheim International GmbH, and scholarship donations from Kyowa Kirin Co., Ltd., Chugai-Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma. H.N has received honoraria from MSD K.K., Astellas pharma Inc., and Merck Biopharma Co., Ltd., research fundings from Chugai-Pharmaceutical Co. Ltd., and a scholarship donation from Bayer AG. Y.A has received honoraria from Chugai-Pharmaceutical Co., Ltd., Bayer Holding Ltd., and research fundings from Chugai-Pharmaceutical Co., Ltd., Geo Holdings Corporation, and BeiGene, Ltd. Y.F has received honoraria from AstraZeneca, Bristol-Myers Squibb Company, Chugai-Pharmaceutical Co., Ltd., DAIICHI SANKYO COMPANY, Micron, MSD, and ONO PHARMACEUTICAL CO., LTD., and research fundings from Abbvie, Amgen, AnHeart, AstraZeneca, Bristol-Myers Squibb Company, Chugai-Pharmaceutical Co., Ltd., Eli Lilly Japan K.K, Incyte, and MSD. J.H has received honoraria from Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma, Ono Pharm, AstraZeneca and Astellas Pharma Inc, and a research grant from Otsuka Pharmaceutical Co., Ltd. H. Kitamura has received honoraria from Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, Bayer AG, and Janssen Pharmaceutical K.K., and scholarship donations from Takeda Pharmaceutical Company Limited and Bayer AG. K. Matsumoto has received honoraria from MSD, Kyowa Kirin Co., Ltd., and Chugai-Pharmaceutical Co., Ltd., and research fundings from DAIICHI SANKYO COMPANY, MSD, Eli Lilly Japan K.K, Gilead Sciences, and Eisai Co., Ltd. E.S has received honoraria from Pfizer Japan Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis Pharmaceuticals Corporation, and Janssen Pharmaceutical K.K. Y.S has received honoraria from AstraZeneca, Kyowa Kirin Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and research fundings from Bayer AG, Baxter, Kyowa Kirin Co., Ltd., and Teijin. Y.Y has received honoraria from AstraZeneca, Mitsubishi Tanabe Pharma, Mochida Pharma, and Astellas Pharma Inc. M. Oya has received honoraria from Astellas, AstraZeneca, Eisai, Ono, MSD, Takeda, Chugai, Novartis Pharma, Bayer, Pfizer, Bristol-Myers Squibb, Merck Biopharma, and Janssen, manuscript fee from Pfizer Japan Inc., research fundings from Ono Pharmaceutical Co., Ltd., Novartis Pharmaceuticals Corporation, MSD, Takeda Pharmaceutical Company Limited, AstraZeneca, Bayer AG, and Astellas Pharma Inc., and subsidies or donations from Chugai-Pharmaceutical Co., Ltd., Sanofi K.K., Ono Pharmaceutical Co., Ltd., Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, and Bayer AG. H. Okada has received honoraria from Astellas, Kyowa Kirin, Daiichi Sankyo, AstraZeneca, Bayer AG, Mitsubishi Tanabe Pharma, Torii Pharma, Ono Pharma, and Boehringer Ingelheim International GmbH, research fundings from Kyowa Kirin, Torii Pharma, Kissei Pharma, and subsidies or donations from Chugai-Pharma, Kyowa Kirin, Ono Pharma, Bayer AG, and Torii Pharma. M. Nangaku has received honoraria from Kyowa Kirin, Mitsubishi Tanabe Pharma, Astellas Pharma, DAIICHI SANKYO, Chugai-Pharma, Bayer AG, AstraZeneca, JT, and Boehringer Ingelheim International GmbH., research fundings from JT, and Bayer AG, and subsidies or donations from Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Limited, Chugai-Pharmaceutical Co., Ltd., Torii Pharmaceutical Co. Ltd, DAIICHI SANKYO COMPANY, and Bayer AG. N. Kashihara has received honoraria from DAIICHI SANKYO, AstraZeneca, Astellas, Otsuka Pharma, Kyowa Kirin, Mitsubishi Tanabe Pharma, and Takeda Pharmaceutical Company Limited, research fundings from AstraZeneca, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co., Ltd., Bayer AG, Kowa Company, Ltd, Nobelpharma Co., Ltd, and DAIICHI SANKYO COMPANY, and subsidies or donations from Kyowa Kirin, Boehringer Ingelheim, Chugai, Otsuka, Bayer AG, Takeda, Mitsubishi Tanabe Pharma, Sumitomo Pharma Astellas, TEIJIN PHARMA, AstraZeneca, MSD, Alexion Pharma, and DAIICHI SANKYO. The other authors declare no potential conflicts of interest.
